Peer Review History

Original SubmissionSeptember 20, 2022
Decision Letter - Mohsen Abbasi-Kangevari, Editor

PONE-D-22-26056The Prevalence and Correlates of Depression among Patients with Chronic Diseases in the United Arab EmiratesPLOS ONE

Dear Dr. Suliman,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please clarify the definitions of each chronic disease investigated in the manuscript. If needed, please also include a section for inclusion and exclusion criteria. A reviewer found the analysis presented in table 2 a bit confusing. Please clarify. The authors have suggested in the paragraph following table 2 that the authors are describing a univariate result analysis. This seems to be the results of a bivariate analysis with Crude Odds Ratios presented. Please clarify. A reviewer also wondered if there was any rational for choosing the Ambulatory Health Services for the recruitment of patients, knowing that patients who present to such services usually come in an acute state. This might influence the way participants respond to the questions on the PHQ questionnaire. Recruiting patients in a more stable environment might give a totally different results.

Please submit your revised manuscript by Dec 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mohsen Abbasi-Kangevari

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a cross-sectional study to examine the prevalence and corelates of depression among a sample of patients with chronic diseases in the UAE. The study is well conducted and presented. I would suggest to scale the y-axis of figure 1 from 0-100.

Reviewer #2: It was a pleasure to review this piece of work. I must say this is an interesting piece of work.

I just have a few comments to make.

1. The article is entitled 'The Prevalence and Correlates of Depression among Patients with Chronic Diseases in the United Arab Emirates'. This suggests that all participants recruited have a chronic medical condition. In the manuscript, I couldn't find anywhere the definition for what was considered a chronic medical condition and how this guided the authors in choosing their participants. I would suggest including a section for inclusion and exclusion criteria. This will make it clearer for the readers.

2. I also found the analysis presented in table 2 a bit confusing, can the authors confirm that everyone who was included in the study had a chronic medical condition? If that was the case then our input variable can be broadly classified into 'present or absent' of a chronic medical condition and the outcome variables will be the correlates or associated factors. A separate table may be used to show the prevalence of depression in the different categories of chronic medical condition present in the participants

3. The authors have suggested in the paragraph following table 2 that the authors are describing a univariate result analysis. This seems to be the results of a bivariate analysis with Crude Odds Ratios presented. Can the authors verify this.

4. I was wondering if there was any rational for choosing the Ambulatory Health Services for the recruitment of patients, knowing that patients who present to such services usually come in an acute state. This might influence the way participants respond to the questions on the PHQ questionnaire. Recruiting patients in a more stable environment might give a totally different results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Stewart Ndutard Ngasa

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to Reviewers Comments

We express our gratitude to both reviewers for taking their time to review our manuscript and provide valuable feedback that has significantly improved our manuscript. We have endeavored to revise our manuscript thoroughly in line with reviewers’ suggestions. To this end, we have provided detailed responses to each comment raised by the reviewers and have mentioned the page and line numbers of changes in the manuscript. We have also incorporated reviewers’ suggestions and submitted the revised manuscript as cleaned and tracked versions.

Reviewer #1 comment:

1. I would suggest to scale the y-axis of figure 1 from 0-100.

Action: Figure 1 y-axis has been rescaled to 0-100

Reviewer #2 (Dr. Stewart Ndutard Ngasa) comments:

Comment 1

The article is entitled 'The Prevalence and Correlates of Depression among Patients with Chronic Diseases in the United Arab Emirates'. This suggests that all participants recruited have a chronic medical condition. In the manuscript, I couldn't find anywhere the definition for what was considered a chronic medical condition and how this guided the authors in choosing their participants. I would suggest including a section for inclusion and exclusion criteria. This will make it clearer for the readers.

Authors’ response:

1- Thank you for the reviewer for pointing out to include a section on inclusion and exclusion criteria and a definition of a chronic medical condition.

Actions:

We have included the definition in the introduction (Page: 4, Line: 100-103). Although we had an inclusion under the section of participants and sample size line 145 we have elaborated more in that section on inclusion criteria. (Page:6, Line :147-148)

Comment 2

2. I also found the analysis presented in table 2 a bit confusing, can the authors confirm that everyone who was included in the study had a chronic medical condition? If that was the case then our input variable can be broadly classified into 'present or absent' of a chronic medical condition and the outcome variables will be the correlates or associated factors. A separate table may be used to show the prevalence of depression in the different categories of chronic medical condition present in the participants

Authors’ response:

2- Yes, all participants in the study had a chronic medical condition.

In Table 2 we studied the association between depression severity (outcome variable) and different demographic and comorbidities characteristics (covariate/factor variables). In this table, categorical variables were analyzed using Chi-square or Fisher’s exact test and continuous variable by Kruskal-Wallis test. Represents a medical condition (e.g. Type I diabetes) with one row (Present or Absent) instead of two rows (No & Yes) will only reduce the number of rows (i.e. table size) since eventually, we will use the Chi-square or Fisher’s exact test to get a p-value to decide if there is a significant association or not between the medical condition and depression severity.

3- We thank the reviewer for this suggestion.

Actions:

1- To improve the understanding of Table 2. We restructured and moved the text describing Table 2 into a separate paragraph, updated the table’s title and added a footnote (Page: 9, Line: 216-220).

2- We added Fig 2 with the prevalence of depression in selected chronic diseases; diseases with adequate representation in the sample to provide an acceptable estimation of prevalence (Page: 8, Line: 206-207).

Comment 3

3. The authors have suggested in the paragraph following table 2 that the authors are describing a univariate result analysis. This seems to be the results of a bivariate analysis with Crude Odds Ratios presented. Can the authors verify this.

Authors’ response

We carried out a univariate logistic regression analysis, in which we examined the association of different characteristics with the presence of depression separately, this means that we fitted many models in each model we had one variable (e.g. age) and the outcome variable (depression). Please note that Tsai in his paper “Achieving consensus on terminology describing multivariable analyses” stated that a regression model studying the effect of single explanatory variable on the response variable is a univariable analysis. Using the term “bivariate” to describe such a model, while common, introduces unnecessary confusion [1].

Action: To avoid confusion, we replaced univariate and multivariable words in the manuscript with unadjusted/simple and adjusted/multiple logistic regression analysis, respectively (Page: 7, Line: 192, 196, 198; Page: 11, Line: 225, 230).

Comment 4

4. I was wondering if there was any rational for choosing the Ambulatory Health Services for the recruitment of patients, knowing that patients who present to such services usually come in an acute state. This might influence the way participants respond to the questions on the PHQ questionnaire. Recruiting patients in a more stable environment might give a totally different results.

Authors’ response:

We agree with the reviewer. However, we chose it as the AHS clinics as those clinics provide the service of diagnosis, treatment, and follow-up with patients with chronic diseases. They have a special clinic for patients with chronic diseases (called CDC clinic). The choice was based on easy access to these patients and to raise awareness among the AHS staffs about the need to follow up on mental health of these patients. I would like to point that all patients receive the PHQ9 as part of the assessment, however, there are no data currently on the prevalence and the needs of mental health support for these patients.

Actions:

We have added an explanation in (Page:5, Line:132-140) for the choice of AHS

References

[1] Tsai AC. Achieving consensus on terminology describing multivariable analyses. Am J Public Health. 2013 Jun;103(6):e1. doi: 10.2105/AJPH.2013.301234. Epub 2013 Apr 18. PMID: 23597350; PMCID: PMC3679183.

Editors Comments and Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Please note that the manuscript was edited as per journal requirement

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Response: Please note that a statement on the consent was added in page 6, line 162-166

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Response: We thank the editor for pointing out this issue.

This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University to be added in funding information

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Please note that we removed information on funding from manuscript. Please add the following statement to the funding information

"This study was funded by SUREPLUS Grant, G00003183 from United Arab Emirates University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: we have uploaded the anonymized data set to a public repository Harvard Dataverse, available at the following DOI https://doi.org/10.7910/DVN/NRJNEN.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Nabeel Al-Yateem, Editor

The Prevalence and Correlates of Depression among Patients with Chronic Diseases in the United Arab Emirates

PONE-D-22-26056R1

Dear Dr. Suliman,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nabeel Al-Yateem, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: All suggestions for improvement have been made by the authors. This article now reads better and I recommend its accepted.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Stewart Ndutard Ngasa

**********

Formally Accepted
Acceptance Letter - Nabeel Al-Yateem, Editor

PONE-D-22-26056R1

The prevalence and correlates of depression among patients with chronic diseases in the United Arab Emirates

Dear Dr. Suliman:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nabeel Al-Yateem

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .